Our Unit has been the first center in the world to include the first patient in the trial LEGIONE . A phase 2 study that evaluates the effectiveness and safety of rozanolixizumab in participants with inactive autoimmune encephalitis of glioma rich in leucine 1. The main investigator of the trial at the Neurology Service of the Regional Hospital in Malaga is Dr. Pedro J. Serrano, head of Neurology Service. The medical research team is composed of Dr. Pablo Cabezudo, Dr. Guillermina García and Dr. Marta Marín. (Ordered by surname) Rehearsal information: Clinical Trials Register Spanish information of the Essay: REEC News in periodical: Link
First Recruiting Site in Europe for the LEGIONE Clinical Trial
Historical article. Study and recruitment information reflects its publication date, not the current status.
Our Unit has been the first center in the world to include the first patient in the trial A phase 2 study that evaluates the effectiveness and safety of rozanolixizumab in participants with inactive autoimmune encephalitis of glioma rich in leucine 1.